论文部分内容阅读
目的通过血糖监测评价利拉鲁肽联合胰岛素治疗2型糖尿病的疗效以及安全性。方法 2014年1月~2015年1月,我院内分泌科住院的2型糖尿病患者,按照标准纳入患者40例,随机分为两组即利拉鲁肽联合胰岛素治疗组和单用胰岛素治疗组。研究对象在接受治疗前和治疗3月后行72小时动态血糖监测(监测项目包括:血糖波动幅度、日间血糖绝对差、血糖波动最大幅度、餐后血糖移动幅度),治疗过程中监测晨起空腹血糖、餐后2h血糖、糖化血红蛋白。结果治疗3月后空腹血糖、糖化血红蛋白、餐后2h血糖两组间差异无统计学意义(P>0.05)。血糖波动幅度、日间血糖绝对差、血糖波动最大幅度、餐后血糖移动幅度两组间差异有统计学意义(P<0.05)。结论利拉鲁肽联合胰岛素可以有效控制2型糖尿病患者血糖,而且可以减少血糖波动,降低低血糖发生率,使2型糖尿病治疗更具安全性。
Objective To evaluate the efficacy and safety of liraglutide combined with insulin in the treatment of type 2 diabetes by blood glucose monitoring. Methods From January 2014 to January 2015, 40 patients with type 2 diabetes mellitus who were hospitalized in Department of Endocrinology of our hospital were randomly divided into two groups, ie, liraglutide plus insulin group and insulin alone group. Subjects underwent 72-hour dynamic glucose monitoring before treatment and after 3 months of treatment (monitoring items included: amplitude of blood glucose fluctuation, absolute difference of blood glucose during the day, maximum amplitude of blood glucose fluctuation and amplitude of postprandial blood glucose movement) during the morning of treatment Fasting blood glucose, 2h postprandial blood glucose, glycosylated hemoglobin. Results There was no significant difference in fasting blood glucose, glycosylated hemoglobin and postprandial 2h blood glucose between the two groups after 3 months of treatment (P> 0.05). Blood glucose fluctuations, absolute differences in blood glucose during the day, the maximum amplitude of blood glucose fluctuations, postprandial blood glucose levels were significantly different between the two groups (P <0.05). Conclusion Liraglutide combined with insulin can effectively control blood sugar in type 2 diabetic patients, and can reduce blood glucose fluctuations, reduce the incidence of hypoglycemia, the treatment of type 2 diabetes more secure.